ONKT 105
Alternative Names: ONKT-105Latest Information Update: 21 Jul 2023
Price :
$50 *
At a glance
- Originator ONK Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 21 Jul 2023 Preclinical trials in Haematological malignancies in Ireland (Parenteral) prior to July 2023 (ONK Therapeutics pipeline, July 2023)
- 21 Jul 2023 Preclinical trials in Solid tumours in Ireland (Parenteral) prior to July 2023 (ONK Therapeutics pipeline, July 2023)
- 01 Jan 2022 ONKT 105 is available for licensing as of 01 Jan 2022. https://www.onktherapeutics.com/